{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T07:47:21Z","timestamp":1767772041823,"version":"3.37.3"},"reference-count":13,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Over the past decade, 2 strategies have advanced the treatment of patients with multiple myeloma and its precursor diseases. First, the definition has changed to include patients without end organ damage, who previously would not have been treated. Second, there is widespread enthusiasm for treating high-risk, smoldering multiple myeloma. In this commentary, we explore the evidence supporting these therapeutic expansions. Although early treatment adds cost and therapeutic burden, it remains unknown whether survival and health-related quality of life are improved by early treatment. Herein, we consider the implications of diagnostic expansion in multiple myeloma.<\/jats:p>","DOI":"10.1182\/blood.2020009752","type":"journal-article","created":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T08:48:04Z","timestamp":1606294084000},"page":"456-458","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":24,"title":["Persistent challenges with treating multiple myeloma early"],"prefix":"10.1182","volume":"137","author":[{"given":"Aaron M.","family":"Goodman","sequence":"first","affiliation":[{"name":"Division of Blood and Marrow Transplantation, Department of Medicine, University of California, San Diego, La Jolla, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2042-1262","authenticated-orcid":false,"given":"Myung S.","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6110-8221","authenticated-orcid":false,"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[{"name":"Department of Medicine and"},{"name":"Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"12","key":"2021012816244274600_B1","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"4","key":"2021012816244274600_B2","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/leu.2012.296","article-title":"Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma","volume":"27","author":"Larsen","year":"2013","journal-title":"Leukemia"},{"issue":"3","key":"2021012816244274600_B3","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/leu.2014.313","article-title":"Classifying ultra-high risk smoldering myeloma","volume":"29","author":"Waxman","year":"2015","journal-title":"Leukemia"},{"issue":"4","key":"2021012816244274600_B4","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/leu.2012.309","article-title":"Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease","volume":"27","author":"Kastritis","year":"2013","journal-title":"Leukemia"},{"issue":"6","key":"2021012816244274600_B5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Cancer J"},{"issue":"7","key":"2021012816244274600_B6","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"P\u00e9rez-Persona","year":"2007","journal-title":"Blood"},{"issue":"10","key":"2021012816244274600_B7","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.3109\/10428194.2013.764419","article-title":"Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study","volume":"54","author":"Cherry","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2021012816244274600_B8","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"2021012816244274600_B9","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrn3475","article-title":"Power failure: why small sample size undermines the reliability of neuroscience [published correction appears in Nat Rev Neurosci. 2013;14(6):451]","volume":"14","author":"Button","year":"2013","journal-title":"Nat Rev Neurosci"},{"year":"2019","key":"2021012816244274600_B10"},{"issue":"11","key":"2021012816244274600_B11","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma","volume":"38","author":"Lonial","year":"2020","journal-title":"J Clin Oncol"},{"author":"International Myeloma Foundation","key":"2021012816244274600_B12","article-title":"Black Swan Research Initiative."},{"issue":"suppl 1","key":"2021012816244274600_B13","article-title":"Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd [abstract]","volume":"134","author":"Mateos","year":"2019","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/4\/456\/1798337\/bloodbld2020009752.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/4\/456\/1798337\/bloodbld2020009752.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T23:46:49Z","timestamp":1611877609000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/137\/4\/456\/474255\/Persistent-challenges-with-treating-multiple"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,28]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,1,28]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020009752","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"type":"print","value":"0006-4971"},{"type":"electronic","value":"1528-0020"}],"subject":[],"published":{"date-parts":[[2021,1,28]]}}}